SCHEMBL3166302

SCHEMBL3166302

CN1CCN(c2ccc(NC(=O)Nc3ccc(Oc4ccncc4)cc3)cc2C(F)(F)F)CC1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRC P12931 5/20 0.72
KDR P35968 5/20 0.55
BRAF P15056 1/20 0.55
MAPK14 Q16539 1/20 0.55
TNNI3K Q59H18 1/20 0.55
ABL1 P00519 4/20 0.54
CSF1R P07333 2/20 0.53
FLT4 P35916 2/20 0.53
PDGFRA P16234 1/20 0.53
FLT3 P36888 1/20 0.53
KCNH2 Q12809 1/20 0.53
CDK1 P06493 1/20 0.52
CDK2 P24941 1/20 0.52
CDK8 P49336 1/20 0.52
FGFR4 P22455 1/20 0.52
KIT P10721 1/20 0.52
RAF1 P04049 5/20 0.50
MAPK13 O15264 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3185956 0.90 SRC (0.60) SRCKDRBRAFMAPK14TNNI3K
SCHEMBL3166786 0.88 RAF1 (0.62) SRCKDRBRAFMAPK14TNNI3K
SCHEMBL19911109 0.83 SRC (1.00) SRCKDRBRAFMAPK14TNNI3K
SCHEMBL14453673 0.82 SRC (0.58) SRCKDRBRAFMAPK14TNNI3K
SCHEMBL13528824 0.81 SRC (0.60) SRCKDRBRAFMAPK14TNNI3K
SCHEMBL3166444 0.80 KDR (0.68) SRCKDRBRAFMAPK14TNNI3K
SCHEMBL4938662 0.79 KDR (0.55) SRCKDRBRAFMAPK14TNNI3K
SCHEMBL939171 0.78 CDK8 (0.70) SRCKDRBRAFMAPK14TNNI3K
SCHEMBL5568335 0.78 KDR (0.67) SRCKDRBRAFMAPK14TNNI3K
SCHEMBL25241289 0.78 NPY2R (0.54) KDRBRAFCSF1RFLT4PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652022-B2 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; NOVARTIS AG (CH) 2010-01-26 US disclosed
US-7652022-B2 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; NOVARTIS AG (CH) 2010-01-26 US disclosed
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases FLOERSHEIMER ANDREAS 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases UCK2, PRKDC, PRKACA SRC 849/4885KDR 3898/4885BRAF 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.